NasdaqGS:NVCRMedical Equipment
NovoCure (NVCR) Is Up 8.4% After First-in-Decades Pancreatic Cancer Approval - Has The Bull Case Changed?
In February 2026, NovoCure announced that the U.S. FDA approved Optune Pax for adult patients with locally advanced pancreatic cancer, to be used alongside gemcitabine and nab-paclitaxel after the Phase 3 PANOVA-3 trial showed a statistically significant overall survival benefit without adding meaningful systemic side effects.
This approval marks the first new treatment option for locally advanced pancreatic cancer in decades and further validates NovoCure’s Tumor Treating Fields technology...